Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Revolutionizing Duchenne Muscular Dystrophy (DMD) Management: Accelerating Drug Development, Clinical Trial Management, and Market Access with DLI Healthcare Consulting | Disease Landscape Insights

This image opens in the lightbox

News provided by

Disease Landscape Insights

21 Sep, 2023, 15:00 GMT

Share this article

Share toX

Share this article

Share toX

LONDON, Sept. 21, 2023 /PRNewswire/ -- Duchenne Muscular Dystrophy (DMD) is a pressing health issue worldwide, impacting countless individuals and families. As per epidemiology study conducted by reliable sources, a significant number of individuals, leading to debilitating muscle degeneration and complications. Growing efforts to develop efficient Duchenne muscular dystrophy treatment and diagnostic solutions are creating a beacon of hope for the patients and their caregivers.


Duchenne Muscular Dystrophy (DMD) is dreadful genetic ailments resulting in continued degeneration of muscle tissues. It is known to develop right from the early childhood with men being the most vulnerable ones. The onset of this disorder leads to muscle weakness, postural issues, and difficulty with activities like walking and running. It is typically caused by a mutation in the dystrophin gene, located on the X chromosome, and follows a recessive inheritance pattern. For any individual to develop DMD, they must inherit two faulty copies of the DMD gene – one from each parent. Innovations in medical research have led to the development of therapies like Vyondys 53, aimed at addressing the underlying genetic mutation responsible for DMD and providing hope for those affected by this condition.

Disease Insights- Symptoms and Characteristics-

The primary Duchenne muscular dystrophy (DMD) symptoms are learning disabilities, contractures, frequent falls, big calves, trouble in getting up or running, and waddling gait, among others. It may also trigger respiratory issues, cardiac problems, and scoliosis, among others. This genetic disorder is known to affect approximately 1 in every 3,500 to 5,000 male births worldwide. This inheritance of this genetic ailment starts right at birth. The symptoms mostly start showing at a tender age of 3-5 years. It is worth mentioning that the degree of severity and course of progression may vary from person to person. Early diagnosis may work wonders in stalling disease progression, thereby improving a patient's quality of life.

Price and Market Access

Unravelling the effective DMD Diagnostic Solutions-

Duchenne Muscular Dystrophy is an extremely rare but complicated disorder. Early and accurate diagnosis is an indispensable tool to ensure proper disease management. If not diagnosed in time, patients may witness severe health complications that can be fatal in some cases. Here are some of the effective DMD diagnostic solutions-

Muscle Biopsy- Muscle biopsy can be conducted to examine the presence of dystrophin in muscle tissue. This enables medical professionals to accurately detect DMD.

Creatinine Kinase Level Test- High levels of creatine kinase (CK) in the blood can be an early indicator of muscle damage. Hence, this test can be quite effective in the diagnosis of Duchenne Muscular Dystrophy and other muscle related conditions.

Genetic Testing- Genetic testing involves analysing a patient's DNA to identify mutations in the DMD gene, which encodes for dystrophin, a protein essential for muscle function. Advances in genetic testing technologies, such as next-generation sequencing, have greatly improved the accuracy and accessibility of genetic diagnosis for DMD.

Learn More About the FDA NDA & BLA Approval (NME) Drugs for Duchenne Muscular Dystrophy (DMD) @

Request_Duchenne Muscular Dystrophy (DMD) Disease

Role of DLI in DMD Management-

DiseaseLandscape Insights will its in depth epidemiology study has paved the way for treatment gap identification in this vertical. This has enabled players to delve into the untapped opportunities in the DMD treatment scenario. They are making continuous R&D efforts to develop effective drugs and therapies to treat this genetic disorder. DLI has been a constant support to players in crucial stages including that of clinical trial management, drug development, regulatory compliance, product portfolio analysis, and clinical trial feasibility analysis, among others. By leveraging DLI's healthcare consulting services, medical researchers and pharma organizations are being equipped with in depth knowledge on DMD disease landscape.  This has helped them to formulate ideal price and market access strategies. Regulatory consulting ability of DLI is also assisting them in understanding the feasibility of their potential products in the market. 

It is worth mentioning that, various players have developed drugs and therapies that have shown promising result in reducing DMD disease burden. Corticosteroids like prednisone and deflazacort, certain physical therapies, NIV, mobility aids, gene therapy, and exon-skipping drugs, are some of the treatment solutions that can alleviate the symptoms of Duchenne dystrophy.

How is DLI helping players in their clinical trial and market access-based endeavours?

Clinical trials are the most crucial phase in the process of drug development. Facilitating such trials comes with numerous challenges, especially in case of DMD due to its extremely rare and complicated nature. DLI has the ability to optimize the clinical trial process for DMD, from protocol design to patient recruitment and data analysis. Their patient-centric approach ensures that trials are conducted efficiently while maintaining the highest standards of safety and ethics. This acceleration of clinical research is vital in getting promising therapies to those who need them urgently.

Discover More About Pricing and Reimbursement, Epidemiology Study, and Healthcare @

https://www.diseaselandscape.com/downloadsample/postid/77

Once a DMD therapy demonstrates safety and efficacy, the next hurdle is ensuring it reaches the patients who can benefit from it. DLI works closely with healthcare providers, payers, and patient advocacy groups to develop market access strategies that optimize the availability and affordability of approved treatments. Their expertise in navigating regulatory and price reimbursement landscapes is invaluable in ensuring that DMD therapies are accessible to all who require them. Post that, DLI also offers players with post launch services which enables their products to solidify their presence in the market over a long period of time. From competitor analysis to product pipeline analysis, this health consultant caters to all such needs.

Unlock the Benefits Today! Get Started Now and Elevate Your Experience @

Checkout_Duchenne Muscular Dystrophy (DMD) Disease

Summing Up-

DMD is a rare and progressive genetic disorder leads to severe health complications if not diagnosed at an early stage. It may impact the mobility, cognitive abilities, respiratory and cardiac health, thereby impacting the patient's overall quality of life. Players have been investing in research & development activities with an aim to formulate effective diagnostic and treatment solutions. But given the rarity and complexity of this ailment, the concerned bodies face several challenges in their endeavours. DLI has emerged as the new found hope for these players. It has been helping players with efficient drug launch strategies, pricing and market access, and product development services, just to name a few.

Related Reports:

Global Landscape of Lung Cancer Services: Insights and Trends

Monkeypox Unveiled: Symptoms, Transmission, and Preventive Measures

Pneumonia Demystified: Symptoms, Causes, and Prevention Strategies

Understanding Lupus: Navigating the Complex Autoimmune Disorder

Comprehensive Guide to Ringworm: Symptoms, Causes, and Effective Treatment

Comprehensive Guide to Diverticulitis: Symptoms, Causes, and Solutions

Regulatory Insights, Disease Landscape, and Market Access Expertise are some of the areas we help you grasp when it comes to strategic Diabetes Disease consulting.

With specialized market entrance techniques, find solutions to HPV disease. Advice on clinical trials and FDA/EMA insights. Investigate now!

Learn about specialized approaches to market access, pricing, and reimbursement for Pancreatic Cancer Disease. Become knowledgeable about clinical trials and market research. Transform your company right away.

Get market insights on Anemia Disease, including KOLs, the FDA, epidemiology, price reimbursement, and more. Your reliable resource for information about anemia. Investigate now!

Symptoms, prevention, and market research on the Chlamydia Disease. Follow updates from the FDA and EMA, epidemiology research, and market entrance strategies.

the Ovarian Cancer Disease market using our tried-and-true tactic. Learn to identify your product's important opinion leaders, to negotiate the regulatory process, and to set a fair pricing.

Navigating Solid Tumor Diseases: Insights and Consulting Services

Demodex Blepharitis: Unveiling Insights and Consulting Services

Unveiling Hope: Navigating Duchenne Muscular Dystrophy (DMD)

Unlocking Relief: Effective Psoriasis Disease Management Strategies

Revolutionizing Parkinson's Disease Care: Global Insights and Innovations

Unlocking the Latest Breakthroughs in Alzheimer's Disease Research: Hope on the Horizon

Rising Against the Odds: Global Insights into Multiple System Atrophy (MSA) Disease

About Disease Landscape:  

Disease Landscape, a pioneering company specializing in Disease Intelligence, Pricing, and Market Access. Utilizing the power of data analytics, Disease Landscape Insights is dedicated to healthcare sector with invaluable, finely crafted insights and recommendations regarding global pricing and market access strategies. As a specialized firm, we are committed to delivering unparalleled insights into pricing and market access, custom-tailored to the healthcare and pharmaceutical industries. Our data-driven solutions and cutting-edge technology position us as your trustworthy partner, offering swift, adaptable, and evidence-based alternatives to traditional market access and pricing research methods.  

Our core competencies encompass Market Research Services, Consulting Services, Global Pricing and Market Access, Epidemiology Studies, as well as Product Portfolio and Pipeline Services. Our expertise lies in furnishing comprehensive data intelligence throughout every phase of drug and device research.  

Contact Us:  

Disease Landscape Insights LLP 
6th Floor, Sr No.207, Office A H 6070 Phase 1 
Solitaire Business Hub, Viman Nagar 
Pune, Maharashtra, 411014 
Email: ajay@diseaselandscape.com    
Email: vishal@diseaselandscape.com 
Blog: https://www.diseaselandscape.com/blogs 
Case Study: https://www.diseaselandscape.com/casestudies  
Pharma consulting Services 
Follow Us: LinkedIn | Twitter | Facebook

Logo: https://mma.prnewswire.com/media/2217060/Disease_Landscape_Insights_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.